FindTrial
Sign In

A Study that will compare two modalities (SIB and SEQ IMRT),commonly being used for the treatment of Locally Advanced Oropharynx, Hypopharynx, Larynx cancer, in terms of acute toxicities, compliance of patients , Locoregional tumor control.

A RANDOMIZED PROSPECTIVE SINGLE INSTITUTIONAL STUDY COMPARING COMPLIANCE, TOXICITY AND LOCOREGIONAL TUMOR CONTROL BETWEEN SIB AND SEQ IMRT FOR LOCALLY ADVANCED OROPHARYNX , HYPOPHARYNX AND LARYNX CANCER

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2019/06/019493
Enrollment
110
Registered
2019-06-03
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: C13- Malignant neoplasm of hypopharynx Health Condition 2: C32- Malignant neoplasm of larynx Health Condition 3: C10- Malignant neoplasm of oropharynx

Interventions

Intervention1: SEQUENTIAL INTENSITY MODULATED RADIOTHERAPY: PATIENTS WITH LOCALLY ADVANCED OROPHARYNX,HYPOPHARYNX,LARYNX CANCER WILL BE GIVEN 70Gy IN 35 FRACTIONS ,5 DAYS A WEEK OVER 7 WEEKS BY SEQUEN

Sponsors

BHAGWAN MAHAVEER CANCER HOSPITAL AND RESEARCH CENTRE
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: PATIENTS WITH LOCALLY ADVANCED OROPHARYNX,HYPOPHARYNX,LARYNX CANCER (STAGE III,IVA) NORMAL RFT,LFT KPS >70%

Exclusion criteria

Exclusion criteria: History of any previous irradiation. History of any surgery for this malignancy Recurrence of disease Pregnancy Collagen disorder Metastatic disease Hypersensitivity to contrast Carcinoma Nasopharynx, Oral cavity.

Design outcomes

Primary

MeasureTime frame
Comparing incidence and severity of acute toxicity between study groups. Comparing compliance to the treatment between study groups. Comparing locoregional tumor control 3 months after completion of treatment between study groups. Timepoint: Comparing incidence and severity of acute toxicity between study groups. Comparing compliance to the treatment between study groups. Comparing locoregional tumor control 3 months after completion of treatment between study groups.—

Secondary

MeasureTime frame
Comparing incidence and severity of acute toxicity between study groups. Comparing compliance to the treatment between study groups. Comparing locoregional tumor control 3 months after completion of treatment between study groups.Timepoint: Comparing incidence and severity of acute toxicity between study groups. Comparing compliance to the treatment between study groups. Comparing locoregional tumor control 3 months after completion of treatment between study groups.—

Countries

India

Contacts

Public ContactDR TEJ PRAKASH SONI

BHAGWAN MAHAVEER CANCER HOSPITAL AND RESEARCH CENTRE

drtejprakashsoni@yahoo.co.in0141510777

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026